XML 110 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Sale of Future Royalties - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2022
Oct. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jan. 01, 2021
Liabilities Related To Sale Of Future Royalties [Line Items]            
Repayment of liability for sale of future royalties     $ 11,726,000 $ 2,474,000 $ 0  
Liability related to sale of future royalties     310,807,000 304,413,000    
Non-cash interest expense for the sale of future royalties     18,083,000 21,108,000 1,450,000  
Collaboration revenue     17,157,000 10,287,000 63,175,000  
GSK            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Collaboration revenue     17,200,000 10,300,000 $ 63,200,000  
JEMPERLI Royalty Monetization Agreement            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Repayment of liability for sale of future royalties     8,600,000      
Issuance costs related to the sale of future royalties   $ 400,000 $ 37,000      
Net of proceeds   249,600,000        
Effective interest rate     8.10%      
JEMPERLI Royalty Monetization Agreement | Sagard            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Proceeds from sale of future royalties   250,000,000        
Royalties agreement, maximum annual royalty payout capacity   1,000,000,000        
Royalties and milestones received     $ 10,400,000      
Liability related to sale of future royalties   250,000,000        
JEMPERLI Royalty Monetization Agreement | Sagard | By the end of 2026            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Royalties and milestones, agreement amount to be received   $ 312,500,000        
Proceeds, contingent on annual sales milestones upfront   125.00%        
JEMPERLI Royalty Monetization Agreement | Sagard | During 2027            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Royalties and milestones, agreement amount to be received   $ 337,500,000        
Proceeds, contingent on annual sales milestones upfront   135.00%        
JEMPERLI Royalty Monetization Agreement | Sagard | At any time after 2027            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Royalties and milestones, agreement amount to be received   $ 412,500,000        
Proceeds, contingent on annual sales milestones upfront   165.00%        
JEMPERLI Royalty Monetization Agreement | GSK            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Non cash royalty revenue, for sale of future royalties       2,300,000    
Non-cash interest expense for the sale of future royalties     17,100,000 20,400,000    
Collaboration revenue     13,800,000 2,300,000    
Zejula Royalty Monetization Agreement            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Repayment of liability for sale of future royalties     $ 3,126,000      
Net of proceeds $ 34,800,000          
Effective interest rate     2.70%      
Zejula Royalty Monetization Agreement | GSK            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Non-cash interest expense for the sale of future royalties     $ 1,000,000 700,000    
Payment rate           1.00%
Settlement agreement rate           0.50%
Effective royalty rate     0.50%      
Collaboration revenue     $ 3,400,000 $ 1,400,000    
Zejula Royalty Monetization Agreement | DRI Healthcare Trust            
Liabilities Related To Sale Of Future Royalties [Line Items]            
Proceeds from sale of future royalties 35,000,000          
Royalties and milestones, agreement amount to be received 10,000,000          
Liability related to sale of future royalties 35,000,000          
Issuance costs related to the sale of future royalties $ 200,000